3.87

0.52% 0.03

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $3.87, with a volume of 8,447. It is up +0.52% in the last 24 hours and down -3.02% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$3.84

Open:

$3.82

24h Volume:

8,447

Relative Volume:

0.01

Market Cap:

$338.38M

Revenue:

$32.77M

Net Income/Loss:

$-101.98M

P/E Ratio:

-0.4027

EPS:

-9.6101

Net Cash Flow:

$-112.43M

1W Performance:

-7.21%

1M Performance:

-3.02%

6M Performance:

+104.23%

1Y Performance:

-82.61%

1-Day Range:

$3.79

$3.88

1-Week Range:

$3.74

$4.21

52-Week Range:

$1.35

$24.43

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1119)

Industry

Biotechnology (624)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

143

Twitter

@x4pharma

Next Earnings Date

2025-03-25

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	3.87	335.76M	32.77M	-101.98M	-112.43M	-9.6101
VRTX Vertex Pharmaceuticals Inc	466.70	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	780.49	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	393.09	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.04	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.03	37.37B	447.02M	-1.18B	-906.14M	-6.1812

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-25	Resumed	Stifel	Buy
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

08:00 AM

Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan

08:00 AM

03:46 AM

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of "Hold" by Analysts - MarketBeat

03:46 AM

01:42 AM

What drives X4 Pharmaceuticals Inc 48Q0 stock priceAnalyst Upgrades & Free Powerful Profit Generation - earlytimes.in

01:42 AM

Jan 05, 2026

Torrent Pharma board gives nod to Rs 12,500-crore bond issue - TradingView — Track All Markets

Jan 05, 2026

Jan 02, 2026

Layoff Tracker: Nido Will Close Following Lead Candidate’s Disappointing Phase II Results - BioSpace

Jan 02, 2026

Jan 01, 2026

What drives X4 Pharmaceuticals Inc stock pricePrice Momentum Alerts & Free Trading Signals to Sharpen Your Edge - earlytimes.in

Jan 01, 2026

4,485 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by Calamos Advisors LLC - MarketBeat

Jan 01, 2026

Dec 31, 2025

More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts - The Business Journals

Dec 31, 2025

Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Grows By 27.1% - Defense World

Dec 31, 2025

Dec 30, 2025

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness - PR Newswire

Dec 30, 2025

Dec 29, 2025

Short Covering: Why X4 Pharmaceuticals Inc 48Q0 stock is a strong buy callJuly 2025 Analyst Calls & Risk Controlled Daily Trade Plans - moha.gov.vn

Dec 29, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN

Dec 29, 2025

Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Cwm LLC - MarketBeat

Dec 29, 2025

Dec 28, 2025

ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat

Dec 28, 2025

Dec 27, 2025

174,077 Shares in Crinetics Pharmaceuticals, Inc. $CRNX Purchased by Rice Hall James & Associates LLC - MarketBeat

Dec 27, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Dec 27, 2025

Dec 24, 2025

Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? - Finviz

Dec 24, 2025

X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon - simplywall.st

Dec 24, 2025

Risks To Shareholder Returns Are Elevated At These Prices For X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - 富途牛牛

Dec 24, 2025

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4 - York Dispatch

Dec 24, 2025

Dec 22, 2025

IndMoney and Federal Bank Savings AccountBull Market Opportunities & Subscribe for Free Weekly Winners - Bollywood Helpline

Dec 22, 2025

Dec 20, 2025

Will X4 Pharmaceuticals Inc. (48Q0) stock boost dividends further2025 Price Targets & Long Hold Capital Preservation Plans - Улправда

Dec 20, 2025

Will X4 Pharmaceuticals Inc. stock continue upward momentumEarnings Trend Report & Safe Entry Trade Signal Reports - Улправда

Dec 20, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Thrivent Financial for Lutherans - MarketBeat

Dec 20, 2025

Dec 19, 2025

Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Price Targets & Free Community Supported Trade Ideas - Улправда

Dec 19, 2025

Can X4 Pharmaceuticals Inc. stock sustain institutional interestMarket Performance Report & Risk Controlled Stock Pick Alerts - Улправда

Dec 19, 2025

Can X4 Pharmaceuticals Inc. stock sustain market leadership2025 Biggest Moves & Advanced Swing Trade Entry Alerts - DonanımHaber

Dec 19, 2025

Day Trade: Can X4 Pharmaceuticals Inc. stock sustain market leadershipQuarterly Market Summary & Daily Stock Momentum Reports - DonanımHaber

Dec 19, 2025

Institution Moves: Can X4 Pharmaceuticals Inc. stock outperform in 2025 bull marketMarket Growth Report & Risk Managed Investment Strategies - DonanımHaber

Dec 19, 2025

Can X4 Pharmaceuticals Inc. stock outperform in 2025 bull marketTrade Entry Report & Capital Efficiency Focused Strategies - DonanımHaber

Dec 19, 2025

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical

Dec 19, 2025

Dec 18, 2025

Merger Talk: Is X4 Pharmaceuticals Inc. stock supported by strong fundamentals2025 Market Trends & Reliable Price Action Trade Plans - Улправда

Dec 18, 2025

Dec 17, 2025

• Position Sizing: Never all in — always size by riskInflation Impact on Stocks & Explosive Capital Gains - Bollywood Helpline

Dec 17, 2025

InMed Pharmaceuticals (INM) reports senior VP employee option expiration - Stock Titan

Dec 17, 2025

Dec 15, 2025

Weekly Analysts’ Ratings Changes for X4 Pharmaceuticals (XFOR) - Defense World

Dec 15, 2025

Dec 14, 2025

Aug Opening: Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Technical Overview & Verified Chart Pattern Trade Signals - moha.gov.vn

Dec 14, 2025

Dec 13, 2025

Bain Capital Life Sciences Investors LLC Sells 16,351,925 Shares of X4 Pharmaceuticals, Inc. $XFOR - MarketBeat

Dec 13, 2025